

# Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis

## Authors

---

Bruno Fattizzo,<sup>1,2</sup> Maria Abbatista,<sup>1</sup> Nicola Cecchi,<sup>1</sup> Cristina Novembrino,<sup>1</sup> Massimo Boscolo-Anzoletti,<sup>1</sup> Giacinto Luca Pedone,<sup>1,2</sup> Marta Bortolotti,<sup>1</sup> Andrea Artoni,<sup>1</sup> Juri Alessandro Giannotta,<sup>1</sup> Flora Peyvandi,<sup>1,2</sup> Francesco Passamonti,<sup>1,2</sup> Wilma Barcellini<sup>1</sup> and Marco Capecchi<sup>1,3</sup>

<sup>1</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan,

Italy; <sup>2</sup>University of Milan, Milan, Italy and <sup>3</sup>Division of Hematology, Gruppo Ospedaliero Moncucco, Lugano, Switzerland

Correspondence:

B. FATTIZZO - [bruno.fattizzo@unimi.it](mailto:bruno.fattizzo@unimi.it)

<https://doi.org/10.3324/haematol.2025.288981>

**Supplementary Table 1.** Incidence rates of thrombotic events (arterial/venous, ATE/VTE) in autoimmune hemolytic anemia AIHA)

	Total observation period (92 patients)	Period without prophylaxis (72 patients)	Period on oral anticoagulants (OAC) (13 patients)	Period on anti-platelet agents (APT) (5 patients)	Period on both OAC and APT (2 patients)
Exposure days→years	183245 →501,7	167326 → 458.1	9249 →25.3	5935 →16.2	735 →2
VTE, n	14	11	2	1	0
ATE, n	4	3	1	0	0
<b>Incidence rate</b> <b>IR *100 pt-yr</b> <b>(95%CI)</b>	<b>Total</b>	<b>No prophylaxis</b>		<b>Prophylaxis *</b>	
VTE	2.8 (1.6-4.6)	2.4 (1.3-4.2)		6.9 (1.9-18.4)	
ATE	0.8 (0.3-1.9)	0.7 (0.2-1.7)		2.3 (0.2- 10.7)	
Total	3.6 (2.2-5.5)	3.1 (1.8-5.0)		9.2 (3.1-21.8)	
Total Cumulative Incidence at 1 year		9.8 (2.9-16.7)		15.4 (-4.2-35)	

\* Among the 4 patients with events occurring while on prophylaxis, 3 patients had a prior thrombotic episode.